International Journal of Hematology

, Volume 83, Issue 5, pp 450–453 | Cite as

Successful Treatment of Refractory Peripheral T-Cell Lymphoma with a Combination of Fludarabine and Cyclophosphamide

  • Masaki Yamaguchi
  • Takeharu Kotani
  • Yoshihisa Nakamura
  • Mikio Ueda
Case Report


We report a case of refractory peripheral T-cell lymphoma (PTCL) successfully treated with a combination of fludarabine and cyclophosphamide (FLU/CY). A 68-year-old man with concurrent PTCL and diffuse large B-cell lymphoma was treated effectively with 3-course CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) therapy, but PTCL relapse occurred and was resistant to ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) therapy. FLU/CY therapy led to complete remission, which was maintained for almost 14 months after a single course. We concluded that a FLU/CY regimen may be useful for attaining long-term remission in patients with refractory relapsed PTCL and should therefore be considered a valuable treatment choice.

Key words

Peripheral T-cell lymphoma Fludarabine Cyclophosphamide 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Armitage JO, Vose JM, Linder J, et al. Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 1989;7:1783–1790.CrossRefPubMedGoogle Scholar
  2. 2.
    Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann Oncol. 1990;1:45–50.CrossRefPubMedGoogle Scholar
  3. 3.
    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma: The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89:3909–3918.Google Scholar
  4. 4.
    Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin’s lymphoma. Blood. 1997;89:4514–4520.PubMedGoogle Scholar
  5. 5.
    Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 2002;13:140–149.CrossRefPubMedGoogle Scholar
  6. 6.
    Whelan JS, Davis CL, Rule S, et al. Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer. 1991;64:120–123.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hochster HS, Kim KM, Green MD, et al. Activity of fludarabine in previously treated non-Hodgkin’s low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol. 1992;10:28–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Redman JR, Cabanillas F, Velasquez WS, et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol. 1992;10:790–794.CrossRefPubMedGoogle Scholar
  9. 9.
    Zinzani PL, Lauria F, Rondelli D, et al. Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin’s lymphoma. Ann Oncol. 1993;4:575–578.CrossRefPubMedGoogle Scholar
  10. 10.
    Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750–1757.CrossRefPubMedGoogle Scholar
  11. 11.
    Koehl U, Li L, Nowak B, et al. Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross-link removal [abstract]. Proc Am Assoc Cancer Res. 1997;38:2. Abstract 10.Google Scholar
  12. 12.
    Frewin R, Turner D, Tighe M, Davies S, Rule S, Johnson S. Combination chemotherapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol. 1999;104:612–613.CrossRefPubMedGoogle Scholar
  13. 13.
    Hochster HS, Oken MM, Winter JN, et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up: a report from the Eastern Cooperative Oncology Group. J Clin Oncol. 2000;18:987–994.CrossRefPubMedGoogle Scholar
  14. 14.
    Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96:71–75.PubMedGoogle Scholar
  15. 15.
    Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070–4078.CrossRefPubMedGoogle Scholar
  16. 16.
    Weisenburger DD, Linder J, Armitage JO. Peripheral T-cell lymphoma: a clinicopathologic study of 42 cases. Hematol Oncol. 1987;5:175–187.CrossRefPubMedGoogle Scholar
  17. 17.
    Lippman SM, Miller TP, Spier CM, Slymen DJ, Grogan TM. The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype. Blood. 1988;72:436–441.PubMedGoogle Scholar
  18. 18.
    Armitage JO, Greer JP, Levine AM, et al. Peripheral T-cell lymphoma. Cancer. 1989;63:158–163.CrossRefPubMedGoogle Scholar
  19. 19.
    Witzig TE, Weitz JJ, Lundberg JH, Tefferi A. Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues. Leuk Lymphoma. 1994;14:137–139.CrossRefPubMedGoogle Scholar
  20. 20.
    Ong ST, Koeppen H, Larson RA, Olopade OI. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. Blood. 1996;88:2354–2355.PubMedGoogle Scholar
  21. 21.
    Hast R, Jacobsson B, Petrescu A, Hjalmar V. Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia. Leuk Lymphoma. 1999;34:597–601.CrossRefPubMedGoogle Scholar
  22. 22.
    Tsatalas C, Margaritis D, Kaloutsi V, Martinis G, Kotsianidis I, Bourikas G. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine. Acta Haematol. 2001;105:106–108.CrossRefPubMedGoogle Scholar
  23. 23.
    Scarisbrick JJ, Child FJ, Clift A, et al. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol. 2001;144:1010–1015.CrossRefPubMedGoogle Scholar
  24. 24.
    Go RS, Gazelka H, Hogan JD, Wester SM. Subcutaneous panni- culitis-like T-cell lymphoma: complete remission with fludarabine. Ann Hematol. 2003;82:247–250.PubMedGoogle Scholar
  25. 25.
    Van Den Neste E, Michaux L, Layios N, et al. High incidence of complications after 2-chloro-2′-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies. Ann Hematol. 2004;83:356–363.CrossRefGoogle Scholar
  26. 26.
    Hirose Y, Fukushima T, Masaki Y, et al. Epstein-Barr virus-associated composite lymphoma composed of peripheral T-cell lymphoma and an anaplastic variant of a diffuse large B-cell type of non-Hodgkin’s lymphoma and strongly expressing p53 protein. Int J Hematol. 2004;79:260–265.CrossRefPubMedGoogle Scholar
  27. 27.
    Tobinai K, Ohtsu T, Hayashi M, et al. Epstein-Barr virus (EBV) genome carrying monoclonal B-cell lymphoma in a patient with adult T-cell leukemia-lymphoma. Leuk Res. 1991;15:837–846.CrossRefPubMedGoogle Scholar
  28. 28.
    Borisch B, Finke J, Hennig I, et al. Distribution and localization of Epstein-Barr virus subtypes A and B in AIDS-related lymphomas and lymphatic tissue of HIV-positive patients. J Pathol. 1992;168:229–236.CrossRefPubMedGoogle Scholar
  29. 29.
    Hamilton-Dutoit SJ, Raphael M, Audouin J, et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood. 1993;82:619–624.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2006

Authors and Affiliations

  • Masaki Yamaguchi
    • 1
  • Takeharu Kotani
    • 1
  • Yoshihisa Nakamura
    • 1
  • Mikio Ueda
    • 1
  1. 1.Department of Hematology and ImmunologyIshikawa Prefectural Central HospitalKanazawaJapan

Personalised recommendations